Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania.

Anywaine, Zacchaeus; Whitworth, Hilary; Kaleebu, Pontiano; Praygod, George; Shukarev, Georgi; Manno, Daniela; Kapiga, Saidi; Grosskurth, Heiner; Kalluvya, Samuel; Bockstal, Viki; +5 more... Anumendem, Dickson; Luhn, Kerstin; Robinson, Cynthia; Douoguih, Macaya; Watson-Jones, Deborah; (2019) Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. The Journal of infectious diseases, 220 (1). pp. 46-56. ISSN 1537-6613 DOI: https://doi.org/10.1093/infdis/jiz070

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1093/infdis/jiz070

Abstract

Share

Download

Filename: Safety-and-Immunogenicity-of-a-2-Dose-Heterologous-Vaccination-Regimen.pdf

Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar